MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF.
Kondo N, Utsumi T, Shimizu Y, Takemoto A, Oh-Hara T, Uchibori K, Subat-Motoshi S, Ninomiya H, Takeuchi K, Nishio M, et al. JCI Insight. 2023 Dec 22; 8(24). Epub 2023 Dec 22.